SYF048b1ec755374616a0ba2bd31c25e0f4Registry ID: 2024-512863-30-00|RecruitingPhase 2
Abatacept for therapy of IgG4-related disease
Deciphering B and T cell Co-stimulation for the Targeted Treatment of IgG4-Related Disease
Loading search results
interventional
N/A
1 country
1
To demonstrate the efficacy of abatacept in reducing the risk of disease recurrence at 48 weeks
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 29, 2024
Actual (reported)Reduction of disease recurrence in patients with IgG4-related disease treated with abatacept compared with placebo-treated pazineti
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Ospedale San Raffaele S.r.l.
Milan, 20132, Italy
Emanuel Della Torre
Emanuel Della Torre
First Submitted
March 29, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
A Study of Efgartigimod in Patients With IgG4-Related Disease
Contact the study team to confirm eligibility.